Stents Global Market - Forecast to 2027

Abstract
Stents are the miniaturized, flexible or expandable tube like structures used to widen and establish patency of the clogged vascular or non-vascular tubular structures and to ensure steady flow of body fluids through them. Compared to the traditional highly invasive surgical repair procedures, the current minimally invasive transcatheter therapeutic procedures with highly efficient, technologically advanced stent products assure patients and healthcare providers with improved efficiency, effectiveness and quicker restoration of the narrowed vessel’s or duct’s natural function. Increased utilization of the various stent products for the numerous and varied types of vascular and non-vascular obstructive conditions and cerebral aneurysm among the patients, elevating inclination of the value centric global patient pool towards the minimally invasive, technologically advanced stent products with better therapeutic outcomes and the need to rapidly mitigate the clinical manifestations associated with blocked vascular and non-vascular hollow organs or weakened vascular bed, reduce hospitalization duration and ease and improve the patient’s condition quickly through efficient and safer interventional products are fuelling the stents global market.
As estimated by IQ4I Research, the stents global market is expected to reach $13,522.8 million by 2027 growing at a mid single digit CAGR from 2020 to 2027, due to increasing prevalence of various kinds of stenotic diseases and cerebral aneurysm across the globe, increasing demand for highly efficient, minimally invasive therapeutic products from the value centric patient population, the trend of coronary stent price slashing and increasing competitiveness of the domestic players in some of the major APAC countries, favorable reimbursement scenario in developed nations, emergence of technologically advanced stent products, persistently escalating geriatric population and the feasibility of even drug eluting stents (DES) in them and the numerous acquisitions and distribution agreements among the stent companies, developing healthcare infrastructural facilities and increasing demand for better healthcare services in the emerging markets. The stents market is segmented by product, material, application, end-users and geography.
Based on the product, the stents global market is segmented into bare metal stents, drug eluting stents (DES), bioresorbable stents and other stents consisting of covered stents and the non-drug eluting polymeric stents. Among these products, the drug eluting stents segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to increasing popularity and adoption of the highly efficient DES across the globe and the constant technological and engineering improvements in these stent products. Bioresorbable stents segment is the fastest emerging segment and is expected of growing at a low teen CAGR during the forecasted period due to increasing research and development activities for the development of highly efficient and safer biodegradable stents that will gradually disappear after improving the patency of the narrowed vessel or duct.
Based on the materials used, the stents global market is segmented into metal alloy based stents and polymer based stents. The metal alloy based stents is further categorized into cobalt-chrome alloy stents, nitinol or nickel-titanium alloy stents, platinum-chromium alloy stents, stainless steel stents and other metallic biomaterial stents like those made up of magnesium, iron and others. The polymer based stents includes stents made up of durable or biostable polymers and biodegradable polymers. In the overall stents market based on materials, the metal alloy based stents segment accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to the increasing utilization of various metallic materials in the production of bare metal stents (BMS), drug eluting stents (DES), covered stents and even the bioresorbable stents and the exhibition of the most desirable and advantageous stent characteristics like high tensile or mechanical strength, elasticity, rigidity and radiopacity by the metallic biomaterials. Among metal alloy based stents, cobalt-chrome alloy stents segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 while nitinol alloy stents segment is the fastest emerging segment and is expected of growing at a mid single digit CAGR from 2020 to 2027. Polymer based stents segment is the fastest emerging segment growing at a high single digit CAGR from 2020 to 2027 due to the escalating utilization of polymers in the manufacturing of DES, covered stents, polymeric non drug eluting stents and the polymeric bioresorbable stents and the manifestation of stent advantageous characteristics like flexibility, elasticity and the controlled drug elution kinetics by the polymers. Among the different kinds of polymer based stents, durable polymer based stents segment accounted for the largest revenue in 2020 and is expected to grow at a high single digit CAGR during the forecasted period while biodegradable polymer based stents segment is the fastest emerging segment growing at a low teen CAGR from 2020 to 2027.
Based on the application, stents global market is broadly classified as vascular and non-vascular stents. Among these, the vascular stents segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to the persistently elevating prevalence of vascular stenotic conditions and cerebral aneurysm across the globe that is in need of various rapid, efficient, technologically advanced and minimally traumatizing therapeutic interventions like stenting. The vascular stents are further segmented into coronary artery stents, peripheral artery stents, neurovascular stents and others consisting of venous stents, vertebral artery stents and pulmonary artery stents. Among these, the coronary artery stent segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 while neurovascular stents segment is the fastest emerging segment and is expected of growing at a high single digit CAGR from 2020 to 2027. Neurovascular stents can be further classified into carotid artery stents, intracranial stents and flow diverter stents for treating cerebral aneurysms. Among the various neurovascular stents, carotid artery stents accounted for the largest revenue in 2020 and is expected to grow at double digit CAGR during 2020 to 2027. Based on the application type, non-vascular stents are segmented into gastrointestinal stents, urinary tract stents or urological stents, airway or tracheobronchial stents or pulmonary stents and others consisting of ophthalmic stents. Among these, the gastrointestinal stents (GI) segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. GI stents are further segmented as pancreatic and biliary stents, colonic or colorectal stents, esophageal stents and duodenal stents. Among these, the Pancreatic & Biliary Stents segment accounted for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027.
Based on the end-users, the stents global market is divided into Hospitals; Ambulatory surgery centers (ASCs) and others consisting of Freestanding or mobile Catheterization Labs and Research Institutes. Among the various end-users, Hospitals segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR during the period 2020 to 2027 due to increased utilization of various types of stent products for the stenting procedures performed in the hospital associated in-patient or out-patient settings. Ambulatory Surgery Centers (ASCs) segment is the fastest emerging segment and is expected of growing at a mid single digit CAGR from 2020 to 2027.
Based on the region, the stents global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Turkey, Rest of Latin America and Middle East & Africa). The major share of the stents global market is occupied by Asia-Pacific in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 mainly due to the persistently elevating prevalence of vascular and non-vascular stenotic conditions in the region, increasing affordability and accessibility of the major stent products like coronary stents among the patients of some of the major countries in the region attributed to government imposed price slashing measures for these life-saving devices, elevating geriatric population impaired with various kinds of vascular or non-vascular obstructive diseases, increasing patient awareness and demand for better, quick minimally invasive, efficient therapeutic procedures with advanced therapeutic products, growing economies of the region, persistently developing healthcare infrastructural facilities in the region, increasing healthcare expenditures and medical tourism aspects of the region. Rest of World (ROW) is the fastest emerging region and is expected of growing at a high single digit CAGR during the forecasted period. The rapid market growth rate of stents market in this region is due to escalating prevalence of vasculature and duct system associated obstructive conditions in the region, increasing geriatric population loaded with various kinds of stenotic conditions, increasing patient awareness and demand for better, quick minimally invasive therapeutic procedures and efficient therapeutic products, growing economies of the region, increasing per capita expenditure on healthcare needs and medical tourism prospects of the region.
The stents global market is consolidated with few companies dominating and occupying major share of the market. Some of the leading players in stents market are Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), Medtronic PLC (Ireland), Terumo Corporation (Japan), Cook Medical LLC (U.S.), Cardinal Health Inc. (U.S.), Becton, Dickinson and company (U.S.), B. Braun Melsungen AG (Germany), Biotronik SE & Co.KG (Germany), Blue Sail Medical Co. Ltd (Biosensors International Pte Ltd) (China) and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Germany
o France
o Italy
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Turkey
o Rest of LATAM and Middle East and Africa

Content

1 EXECUTIVE SUMMARY 23
2 INTRODUCTION 32
2.1 KEY TAKEAWAYS 32
2.2 SCOPE OF THE REPORT 33
2.3 REPORT DESCRIPTION 33
2.4 MARKETS COVERED 38
2.5 STAKEHOLDERS 40
2.6 RESEARCH METHODOLOGY 41
2.6.1 MARKET SIZE ESTIMATION 43
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 46
2.6.3 SECONDARY SOURCES 47
2.6.4 PRIMARY SOURCES 48
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 48
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 49
2.6.7 ASSUMPTIONS 49
3 MARKET ANALYSIS 52
3.1 INTRODUCTION 52
3.2 MARKET SEGMENTATION 54
3.3 FACTORS INFLUENCING MARKET 56
3.3.1 DRIVERS AND OPPORTUNITIES 57
3.3.1.1 Escalating prevalence of vascular and non-vascular stenotic diseases and cerebral aneurysm 57
3.3.1.2 Elevating inclination towards minimally invasive therapeutic approaches 59
3.3.1.3 The trend of coronary stent price slashing and increasing competitiveness of domestic players in apac countries 61
3.3.1.4 Emergence of technologically advanced products 63
3.3.1.5 Escalating geriatric population and feasibility of drug eluting stents in them 65
3.3.1.6 Acquisitions and distribution agreements to open an array of opportunities for the market to flourish 66
3.3.1.7 Favourable reimbursement policies escalating stent technology diffusion in developed nations 67
3.3.2 RESTRAINTS AND THREATS 68
3.3.2.1 Stringent regulatory bodies guiding stent manufacturers 68
3.3.2.2 The threat of commercialized stent recalls 71
3.3.2.3 Lack of skilled, experienced and trained healthcare professionals 72
3.3.2.4 Adverse effects of stents 74
3.3.2.5 Concerns over irrational stenting and under-performance of stents in complex stenotic diseases or lesions 75
3.4 REGULATORY AFFAIRS 77
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 77
3.4.1.1 ISO 9001: 2015 quality management system 77
3.4.1.2 ISO 14644-1 clean room standards 77
3.4.1.3 ISO 13485 medical devices 78
3.4.1.4 ISO 10993 biological evaluation of medical devices 78
3.4.1.5 ISO 14971: risk management of medical devices 79
3.4.1.6 ISO 25539-2:2020 cardiovascular implants — endovascular devices — part 2: vascular stents 79
3.4.1.7 ISO 25539-1 79
3.4.1.8 ISO 12417-1 80
3.4.1.9 ISO/TS 17137 80
3.4.1.10 ISO 17327-1 80
3.4.1.11 IEC 60601-1 medical electrical equipment standard 80
3.4.2 ASTM INTERNATIONAL STANDARDS 80
3.4.3 U.S. 81
3.4.4 CANADA 84
3.4.5 EUROPE 84
3.4.6 JAPAN 85
3.4.7 CHINA 86
3.4.8 INDIA 88
3.5 TECHNOLOGICAL ADVANCEMENTS 90
3.5.1 INTRODUCTION 90
3.5.2 SMART STENTS 90
3.5.3 3D-PRINTED STENTS 91
3.5.4 INDIRECT 4D PRINTING AND MICROSTENTS 91
3.5.5 NANOCOATED NON-DRUG ELUTING STENT AND ULTRASHORT DAPT 92
3.5.6 BIOENGINEERED STENTS 92
3.5.7 GENE ELUTING STENTS (GES) 92
3.5.8 BIORESORBABLE STENTS 93
3.6 STENTS COATING MATERIALS 94
3.6.1 INORGANIC COATING MATERIALS 95
3.6.2 ORGANIC COATING MATERIALS 96
3.6.3 BIOLOGICAL COATING MATERIALS OR BIOCOATINGS 98
3.6.4 CHEMOTHERAPUTICS OR DRUGS 101
3.7 PORTER’S FIVE FORCE ANALYSIS 104
3.7.1 THREAT OF NEW ENTRANTS 105
3.7.2 THREAT OF SUBSTITUTES 107
3.7.3 BARGAINING POWER OF SUPPLIERS 108
3.7.4 BARGAINING POWER OF BUYERS 109
3.7.5 COMPETITIVE RIVALRY 109
3.8 SUPPLY CHAIN ANALYSIS 111
3.9 REIMBURSEMENT SCENARIO 119
3.10 PATENT TRENDS 123
3.11 REGULATORY APPROVAL ANALYSIS 125
3.12 CLINICAL TRIALS 137
3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 139
3.13.1 STENTS GLOBAL MARKET SHARE ANALYSIS 139
3.13.2 CORONARY STENTS GLOBAL MARKET SHARE ANALYSIS 142
3.13.3 PERIPHERAL STENTS GLOBAL MARKET SHARE ANALYSIS 146
3.13.4 NEUROVASCULAR STENTS GLOBAL MARKET SHARE ANALYSIS 149
3.13.4.1 Flow diverters global market share analysis 152
3.13.4.2 Intracranial stent global market share analysis 154
3.13.4.3 Carotid stent global market share analysis 156
3.13.5 GASTROINTESTINAL STENTS GLOBAL MARKET SHARE ANALYSIS 158
3.13.6 DRUG ELUTING STENTS GLOBAL MARKET SHARE ANALYSIS 161
3.14 STENTS - NUMBER OF PROCEDURES BY REGION 164
3.14.1 CORONARY STENT IMPLANTATION PROCEDURAL VOLUME BY REGION 164
3.14.2 PERIPHERAL STENT IMPLANTATION PROCEDURAL VOLUME BY REGION 166
3.15 STENTS COMPANY COMPARISON TABLE BY REVENUE, PRODUCT, PRODUCT TYPE, APPLICATION, MATERIAL AND INDICATION 168
4 STENTS GLOBAL MARKET, BY PRODUCT 195
4.1 INTRODUCTION 195
4.2 BARE METAL STENTS 199
4.3 DRUG ELUTING STENTS 203
4.4 BIORESORBABLE STENTS 208
4.5 OTHER STENTS 215
5 STENTS GLOBAL MARKET, BY MATERIAL 219
5.1 INTRODUCTION 219
5.2 METAL ALLOY BASED STENTS 223
5.2.1 COBALT CHROME ALLOY STENTS 228
5.2.2 NITINOL ALLOY STENTS 231
5.2.3 STAINLESS STEEL STENTS 234
5.2.4 PLATINUM ALLOY STENTS 237
5.2.5 OTHER METAL ALLOY STENTS 240
5.3 POLYMER BASED STENTS 243
5.3.1 DURABLE POLYMER STENTS 248
5.3.2 BIODEGRADABLE POLYMER STENTS 253
6 STENTS GLOBAL MARKET, BY APPLICATION 256
6.1 INTRODUCTION 256
6.2 VASCULAR STENTS 259
6.2.1 CORONARY ARTERY STENTS 264
6.2.2 PERIPHERAL ARTERY STENTS 268
6.2.3 NEUROVASCULAR STENTS 273
6.2.3.1 Carotid artery stents 277
6.2.3.2 Intracranial stents 280
6.2.3.3 Flow diverter stents 284
6.2.4 RENAL ARTERY STENTS 286
6.2.5 OTHER VASCULAR STENTS 289
6.3 NON-VASCULAR STENTS 294
6.3.1 GASTROINTESTINAL STENTS 300
6.3.1.1 Pancreatic & biliary stents 305
6.3.1.2 Colorectal stents 309
6.3.1.3 Esophageal stents 312
6.3.1.4 Duodenal stents 316
6.3.2 UROLOGICAL STENTS 319
6.3.3 AIRWAY STENTS 323
6.3.4 OTHER NON-VASCULAR STENTS 326
7 STENTS GLOBAL MARKET, BY END-USERS 329
7.1 INTRODUCTION 329
7.2 HOSPITALS 332
7.3 AMBULATORY SURGERY CENTERS 336
7.4 OTHER END-USERS 339
8 REGIONAL ANALYSIS 343
8.1 INTRODUCTION 343
8.2 NORTH AMERICA 348
8.2.1 U.S. 368
8.2.2 REST OF NORTH AMERICA 376
8.3 EUROPE 386
8.3.1 GERMANY 406
8.3.2 FRANCE 413
8.3.3 ITALY 419
8.3.4 REST OF EUROPE 425
8.4 APAC 434
8.4.1 CHINA 454
8.4.2 JAPAN 462
8.4.3 INDIA 469
8.4.4 REST OF APAC 478
8.5 REST OF THE WORLD 486
8.5.1 BRAZIL 506
8.5.2 TURKEY 512
8.5.3 REST OF LATAM AND MEA 518
9 COMPETITIVE LANDSCAPE 526
9.1 INTRODUCTION 526
9.2 PRODUCT APPROVAL 528
9.3 CLINICAL STUDIES/INVESTIGATIONS 531
9.4 PRODUCT LAUNCH 534
9.5 ACQUISITION 536
9.6 OTHER DEVELOPMENTS 536
10 MAJOR COMPANIES 539
10.1 ABBOTT LABORATORIES 539
10.1.1 OVERVIEW 539
10.1.2 FINANCIALS 540
10.1.3 PRODUCT PORTFOLIO 544
10.1.4 KEY DEVELOPMENTS 545
10.1.5 BUSINESS STRATEGY 546
10.1.6 SWOT ANALYSIS 547
10.2 B. BRAUN MELSUNGEN AG 548
10.2.1 OVERVIEW 548
10.2.2 FINANCIALS 549
10.2.3 PRODUCT PORTFOLIO 552
10.2.4 KEY DEVELOPMENTS 552
10.2.5 BUSINESS STRATEGY 553
10.2.6 SWOT ANALYSIS 554
10.3 BECTON, DICKINSON AND COMPANY 555
10.3.1 OVERVIEW 555
10.3.2 FINANCIALS 556
10.3.3 PRODUCT PORTFOLIO 560
10.3.4 KEY DEVELOPMENTS 561
10.3.5 BUSINESS STRATEGY 561
10.3.6 SWOT ANALYSIS 562
10.4 BIOTRONIK SE & CO. KG 563
10.4.1 OVERVIEW 563
10.4.2 FINANCIALS 563
10.4.3 PRODUCT PORTFOLIO 564
10.4.4 KEY DEVELOPMENTS 565
10.4.5 BUSINESS STRATEGY 567
10.4.6 SWOT ANALYSIS 568
10.5 BLUE SAIL MEDICAL CO. LTD (BIOSENSORS INTERNATIONAL PTE LTD.) 569
10.5.1 OVERVIEW 569
10.5.2 FINANCIALS 569
10.5.3 PRODUCT PORTFOLIO 570
10.5.4 KEY DEVELOPMENTS 570
10.5.5 BUSINESS STRATEGY 571
10.5.6 SWOT ANALYSIS 572
10.6 BOSTON SCIENTIFIC CORPORATION 573
10.6.1 OVERVIEW 573
10.6.2 FINANCIALS 574
10.6.3 PRODUCT PORTFOLIO 579
10.6.4 KEY DEVELOPMENTS 581
10.6.5 BUSINESS STRATEGY 582
10.6.6 SWOT ANALYSIS 583
10.7 CARDINAL HEALTH INC. 584
10.7.1 OVERVIEW 584
10.7.2 FINANCIALS 585
10.7.3 PRODUCT PORTFOLIO 589
10.7.4 KEY DEVELOPMENTS 589
10.7.5 BUSINESS STRATEGY 590
10.7.6 SWOT ANALYSIS 591
10.8 COOK MEDICAL LLC 592
10.8.1 OVERVIEW 592
10.8.2 FINANCIALS 592
10.8.3 PRODUCT PORTFOLIO 593
10.8.4 KEY DEVELOPMENTS 595
10.8.5 BUSINESS STRATEGY 596
10.8.6 SWOT ANALYSIS 597
10.9 MEDTRONIC PLC 598
10.9.1 OVERVIEW 598
10.9.2 FINANCIALS 599
10.9.3 PRODUCT PORTFOLIO 604
10.9.4 KEY DEVELOPMENTS 605
10.9.5 BUSINESS STRATEGY 606
10.9.6 SWOT ANALYSIS 607
10.10 TERUMO CORPORATION 608
10.10.1 OVERVIEW 608
10.10.2 FINANCIALS 609
10.10.3 PRODUCT PORTFOLIO 612
10.10.4 KEY DEVELOPMENTS 612
10.10.5 BUSINESS STRATEGY 614
10.10.6 SWOT ANALYSIS 615

LIST OF TABLES
TABLE 1 STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 30
TABLE 2 AVERAGE SELLING PRICE (ASP) OF BARE METAL STENTS, DRUG ELUTING STENTS, COVERED STENTS AND BIORESORBABLE STENTS (2020) ($) 51
TABLE 3 CORONARY STENT IMPLANTATION PROCEDURES, BY REGION, (2019-2027) (NO’S) 165
TABLE 4 PERIPHERAL STENT IMPLANTATION PROCEDURES, BY REGION, (2019-2027) (NO’S) 167
TABLE 5 STENTS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN) 197
TABLE 6 BARE METAL STENTS GLOBAL MARKET REVENUE,
BY REGION, (2019-2027) ($MN) 202
TABLE 7 DRUG ELUTING STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 207
TABLE 8 BIORESORBABLE STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 214
TABLE 9 OTHER STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 218
TABLE 10 STENTS GLOBAL MARKET REVENUE, BY MATERIAL, (2019-2027) ($MN) 221
TABLE 11 METAL ALLOY BASED STENTS GLOBAL MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 225
TABLE 12 METAL ALLOY BASED STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 227
TABLE 13 COBALT CHROME ALLOY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 230
TABLE 14 NITINOL ALLOY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 233
TABLE 15 STAINLESS STEEL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 236
TABLE 16 PLATINUM ALLOY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 239
TABLE 17 OTHER METAL ALLOY BASED STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 242
TABLE 18 POLYMER BASED STENTS GLOBAL MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 245
TABLE 19 POLYMER BASED STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 247
TABLE 20 DURABLE POLYMER BASED STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 251
TABLE 21 BIODEGRADABLE POLYMER BASED STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 255
TABLE 22 STENTS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 257
TABLE 23 VASCULAR STENTS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 261
TABLE 24 VASCULAR STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 263
TABLE 25 CORONARY ARTERY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 267
TABLE 26 PERIPHERAL ARTERY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 272
TABLE 27 NEUROVASCULAR STENTS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 274
TABLE 28 NEUROVASCULAR STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 276
TABLE 29 CAROTID ARTERY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 279
TABLE 30 INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 282
TABLE 31 FLOW DIVERTERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 285
TABLE 32 RENAL ARTERY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 288
TABLE 33 OTHER VASCULAR STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 293
TABLE 34 NON-VASCULAR STENTS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 296
TABLE 35 NON-VASCULAR STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 298
TABLE 36 GASTROINTESTINAL STENTS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 302
TABLE 37 GASTROINTESTINAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 304
TABLE 38 PANCREATIC & BILIARY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 308
TABLE 39 COLORECTAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 311
TABLE 40 ESOPHAGEAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 314
TABLE 41 DUODENAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 318
TABLE 42 UROLOGICAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 322
TABLE 43 AIRWAY STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 325
TABLE 44 OTHER NON-VASCULAR STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 328
TABLE 45 STENTS GLOBAL MARKET REVENUE, BY END-USERS, (2019-2027) ($MN) 330
TABLE 46 HOSPITALS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 335
TABLE 47 AMBULATORY SURGERY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 338
TABLE 48 OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 342
TABLE 49 STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN) 345
TABLE 50 NORTH AMERICA STENTS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN) 352
TABLE 51 NORTH AMERICA STENTS MARKET REVENUE, BY MATERIAL, (2019-2027) ($MN) 353
TABLE 52 NORTH AMERICA METAL ALLOY BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 354
TABLE 53 NORTH AMERICA POLYMER BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 355
TABLE 54 NORTH AMERICA STENTS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 356
TABLE 55 NORTH AMERICA VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 357
TABLE 56 NORTH AMERICA NEUROVASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 358
TABLE 57 NORTH AMERICA NON-VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 359
TABLE 58 NORTH AMERICA GASTROINTESTINAL STENTS MARKET REVENUE, BY APPLICATION TYPE (2019-2027) ($MN) 360
TABLE 59 NORTH AMERICA STENTS MARKET REVENUE, BY END-USERS (2019-2027) ($MN) 361
TABLE 60 NORTH AMERICA STENTS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 366
TABLE 61 EUROPE STENTS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN) 390
TABLE 62 EUROPE STENTS MARKET REVENUE, BY MATERIAL, (2019-2027) ($MN) 391
TABLE 63 EUROPE METAL ALLOY BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 392
TABLE 64 EUROPE POLYMER BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 393
TABLE 65 EUROPE STENTS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 394
TABLE 66 EUROPE VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 395
TABLE 67 EUROPE NEUROVASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 396
TABLE 68 EUROPE NON-VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 397
TABLE 69 EUROPE GASTROINTESTINAL STENTS MARKET REVENUE, BY APPLICATION TYPE (2019-2027) ($MN) 398
TABLE 70 EUROPE STENTS MARKET REVENUE, BY END-USERS (2019-2027) ($MN) 399
TABLE 71 EUROPE STENTS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 404
TABLE 72 APAC STENTS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN) 438
TABLE 73 APAC STENTS MARKET REVENUE, BY MATERIAL, (2019-2027) ($MN) 439
TABLE 74 APAC METAL ALLOY BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 440
TABLE 75 APAC POLYMER BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 441
TABLE 76 APAC STENTS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 442
TABLE 77 APAC VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 443
TABLE 78 APAC NEUROVASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 444
TABLE 79 APAC NON-VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 445
TABLE 80 APAC GASTROINTESTINAL STENTS MARKET REVENUE, BY APPLICATION TYPE (2019-2027) ($MN) 446
TABLE 81 APAC STENTS MARKET REVENUE, BY END-USERS (2019-2027) ($MN) 447
TABLE 82 APAC STENTS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 452
TABLE 83 ROW STENTS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN) 490
TABLE 84 ROW STENTS MARKET REVENUE, BY MATERIAL, (2019-2027) ($MN) 491
TABLE 85 ROW METAL ALLOY BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 492
TABLE 86 ROW POLYMER BASED STENTS MARKET REVENUE, BY MATERIAL TYPE, (2019-2027) ($MN) 493
TABLE 87 ROW STENTS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN) 494
TABLE 88 ROW VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 495
TABLE 89 ROW NEUROVASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 496
TABLE 90 ROW NON-VASCULAR STENTS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN) 497
TABLE 91 ROW GASTROINTESTINAL STENTS MARKET REVENUE, BY APPLICATION TYPE (2019-2027) ($MN) 498
TABLE 92 ROW STENTS MARKET REVENUE, BY END-USERS (2019-2027) ($MN) 499
TABLE 93 ROW STENTS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN) 504
TABLE 94 PRODUCT APPROVAL (2019 – 2020) 528
TABLE 95 CLINICAL STUDIES/INVESTIGATIONS (2019 - 2020) 531
TABLE 96 PRODUCT LAUNCH (2019 – 2020) 534
TABLE 97 ACQUISITION (2019 – 2020) 536
TABLE 98 OTHER DEVELOPMENTS (2019 – 2020) 537
TABLE 99 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN) 540
TABLE 100 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2018-2020) ($MN) 541
TABLE 101 ABBOTT LABORATORIES: MEDICAL DEVICE REVENUE, BY SUB-SEGMENTS (2018-2020) ($MN) 542
TABLE 102 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN) 543
TABLE 103 B.BRAUN MELSUNGEN: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN) 549
TABLE 104 B.BRAUN MELSUNGEN: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN) 550
TABLE 105 B.BRAUN MELSUNGEN: TOTAL REVENUE BY, GEOGRAPHY, (2017-2019) ($MN) 551
TABLE 106 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN) 556
TABLE 107 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE BY PRODUCT SEGMENTS, (2018-2020) ($MN) 557
TABLE 108 BECTON, DICKINSON AND COMPANY: INTERVENTIONAL REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN) 558
TABLE 109 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE BY GEOGRAPHY, (2018-2020) ($MN) 559
TABLE 110 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN) 574
TABLE 111 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN) 575
TABLE 112 BOSTON SCIENTIFIC CORPORATION: CARDIOVASCULAR REVENUE BY SUB-SEGMENTS, (2018-2020) ($MN) 576
TABLE 113 BOSTON SCIENTIFIC CORPORATION: MEDSURG REVENUE BY SUB-SEGMENTS, (2018-2020) ($MN) 577
TABLE 114 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 578
TABLE 115 CARDINAL HEALTH: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN) 585
TABLE 116 CARDINAL HEALTH: TOTAL REVENUE, BY SEGMENTS (2019-2021) ($MN) 586
TABLE 117 CARDINAL HEALTH: MEDICAL REVENUE, BY SUB-SEGMENTS, (2019-2021) ($MN) 587
TABLE 118 CARDINAL HEALTH: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN) 588
TABLE 119 MEDTRONIC PLC.: TOTAL SALES AND R&D EXPENSES, (2018-2020) ($MN) 599
TABLE 120 MEDTRONIC PLC.: TOTAL SALES, BY SEGMENTS, (2018-2020) ($MN) 600
TABLE 121 MEDTRONIC PLC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN) 601
TABLE 122 MEDTRONIC PLC: RESTORATIVE THERAPIES GROUP REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN) 602
TABLE 123 MEDTRONIC PLC.: TOTAL SALES, BY GEOGRAPHY, (2018-2020)($MN) 603
TABLE 124 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN) 609
TABLE 125 TERUMO CORPORATION: TOTAL REVENUE, BY PRODUCT SEGMENTS, (2018-2020) ($MN) 610
TABLE 126 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN) 611